Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Banyu develops factor Xa inhibitors as antiplatelet/antithrombotic agents

April 2, 1998

Preliminary results of TIMI 15A trial reported at ACC

April 1, 1998

Anticoagulants in development at DuPont Merck

April 1, 1998

Potent and selective PDE III inhibitor in development at Otsuka

March 31, 1998

New antiplatelet and antithrombotic agent characterized by Taisho

March 31, 1998

Toyama researchers characterize antiplatelet/antithrombotic effects of T-250

March 31, 1998

Platelet antiaggregatory effects of liposome-encapsulated streptokinase

March 30, 1998

Z-335 demonstrates beneficial effects in models of peripheral circulatory insufficiency

March 30, 1998

DuPont Merck obtains U.S. rights for anticoagulant

March 27, 1998

Selective factor Xa inhibitors in development at Banyu

March 25, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.